Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Director departure
|
|
Anthera Pharmaceuticals Inc (ANTH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/27/2018 |
GN
| Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets |
| 05/04/2018 |
GN
| New Research: Key Drivers of Growth for Global Medical REIT, DXP Enterprises, SJW, FTI Consulting, Anthera Pharmaceuticals, and Alexandria Real Estate Equities — Factors of Influence, Major Initiatives and Sustained Production |
| 03/07/2018 |
GN
| Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference |
| 03/06/2018 |
GN
| Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria |
| 02/08/2018 |
GN
| Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey's 4th Annual Orphan Drug Day |
| 02/05/2018 |
GN
| Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura |
| 01/25/2018 |
GN
| Anthera Receives Positive Nasdaq Listing Determination |
| 01/22/2018 |
GN
| Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter |
| 01/17/2018 |
GN
| Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet — New Horizons, Emerging Trends, and Upcoming Developments |
| 01/09/2018 |
GN
| Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering |
| 01/08/2018 |
GN
| Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders |
| 12/11/2017 |
GN
| Anthera Pharmaceuticals Announces Positive Outcome of Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura |
| 11/17/2017 |
GN
| Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal |
| 11/09/2017 |
GN
| Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura |
| 11/06/2017 |
GN
| Anthera Pharmaceuticals Provides Business Update and Reports 2017 Third Quarter Financial Results |
| 11/05/2017 |
GN
| Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting |
| 11/02/2017 |
GN
| Anthera Pharmaceuticals Announces Presentations of Sollpura Data at the North American Cystic Fibrosis Conference |
| 11/01/2017 |
GN
| Anthera Pharmaceuticals Announces Presentation of Blisibimod Lupus Research at the American Society of Nephrology Annual Meeting |
| 10/24/2017 |
GN
| Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering |
| 09/07/2017 |
GN
| Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in RESULT Phase 3 Clinical Study of Sollpura in Cystic Fibrosis |
| 09/05/2017 |
GN
| Anthera Pharmaceuticals to Participate in the Citi 12th Annual Biotech Conference |
| 08/14/2017 |
GN
| Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network |
| 08/09/2017 |
GN
| Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy |
| 08/09/2017 |
GN
| Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results |
| 07/10/2017 |
GN
| Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development Network |
| 07/06/2017 |
GN
| Anthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura |
| 05/10/2017 |
GN
| Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results |
| 04/28/2017 |
GN
| Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock |
| 03/29/2017 |
GN
| Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura |
| 03/14/2017 |
GN
| ANTH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017 |
| 03/14/2017 |
GN
| Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants |
| 03/03/2017 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc. |
| 02/27/2017 |
GN
| Anthera Pharmaceuticals Provides Business Update and Reports 2016 Fourth Quarter and Fiscal Year Financial Results |
| 02/24/2017 |
GN
| IMPORTANT ANTHERA PHARMACEUTICALS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers of Anthera Pharmaceuticals, Inc. |
|
|
|